A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
A legfontosabb adatok
- Ki végzi
- Pfizer
- Hol
- Hamamatsu, Koto-ku, Kurume, Mitaka, Niigata, Osaka, Sendai és Shinjuku-ku (Japán)Mind a 8 helyszín megnézéseMég 10 másik országban, 135 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 674 fő, tervezett
- Kezdés
- 2025. ápr. 1.
- Várható befejezés
- 2028. márc. 19.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Ritlecitinib 100 mg
- Ritlecitinib 50 mg
- Placebo - 100 mg
- Placebo - 50 mg
- A regiszteradat frissítve
- 2026. október 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 12 and older with alopecia areata, a disease that causes hair loss. They must have lost 50% or more of their scalp hair.
- Életkor
- 12 years and older. Part 2 takes only teenagers 12 to <18 years who were not in Part 1. Teenagers can join only where local approvals allow it.
- Nem
- All sexes can join.
- A betegség stádiuma
- Alopecia areata with ≥50% scalp hair loss (measured by SALT), no other cause of hair loss, no regrowth of full hair in the previous 6 months, and a current episode lasting ≤10 years.
- Korábbi kezelés
- People must be willing to stop all other alopecia areata treatments. People who took ritlecitinib in Study B7981094 or other ritlecitinib studies cannot join. No study drug or vaccine within 8 weeks or 5 half-lives, whichever is longer.
- Biomarker vagy leletérték
- Teenagers need proof of 2 doses of chickenpox (varicella) vaccine or a positive VZV IgG blood test.
A részvétel fő kizáró okai
- Other conditions that cause hair loss or affect the scalp
- Recent serious infection, tuberculosis, hepatitis B or hepatitis C, or spread-out or repeated shingles
- Worsening or sudden hearing loss, or middle or inner ear disease
- Cancer, lymphoma or leukemia, except some treated skin cancers or cervical carcinoma in situ
- Psychiatric conditions, including recent suicidal thoughts or behavior
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Age:
- 18 years of age or older at screening. Adolescents (12 to <18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled. In Part 2 of the study, only adolescents (12 to <18 years of age at both Screening and Day 1) who did not participate in Part 1 will be enrolled; Disease Characteristics:
- Must meet the following alopecia areata criteria at both Screening and Baseline:; Have a clinical diagnosis of alopecia areata with no other etiology of hair loss; ≥50% hair loss of the scalp, as measured by SALT, without evidence of terminal hair regrowth within the previous 6 months; Current episode of hair loss ≤10 years
Ki nem vehet részt
- General Infection History:; Have a history of systemic infection requiring hospitalization or parenteral therapy (antimicrobial, antiviral, antiparasitic, antiprotozoal, or antifungal), or as otherwise judged clinically significant by the investigator, within 3 months prior to Day 1; Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves; Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis
- Adolescent participants 12 to <18 years of age without one of the following:; Documented evidence from a health professional of having received varicella vaccination (2 doses); or; Evidence of prior exposure to varicella zoster virus (VZV) based on serological testing (ie, a positive VZV IgG Ab result) at Screening
- Current or prior use of any prohibited medication(s), vaccine(s), or treatment(s) within the protocol-defined timelines; Prior/Concurrent Clinical Study Experience:
- Previous administration with an investigational drug or vaccine within 8 weeks (or longer as determined by the local requirement) or 5 half-lives (whichever is longer) before the first dose of study intervention in this study. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study. Receipt of study intervention in Study B7981094 or other studies of ritlecitinib; Diagnostic Assessments:
- Medical Conditions:
- Diseases or conditions other than alopecia areata which affect hair loss, including other types of alopecia, other scalp disease that may impact the alopecia areata assessment, or active systemic diseases that may cause hair loss
- History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention
- Any psychiatric condition including recent or active suicidal ideation or behavior that meets protocol-defined criteria
- Specific Viral Infection History:; History (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster; Infected with hepatitis B or hepatitis C viruses: all participants will undergo screening for hepatitis B and C for eligibility
- Other Medical Conditions:; Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating or progressive; Abnormal findings on the screening chest imaging (eg, chest x-ray) including, but not limited to, presence of active TB or other infections, cardiomyopathy, or malignancy. Chest imaging may be performed up to 12 weeks prior to Screening; Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ; Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease; Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery
- Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study; Prior/Concomitant Therapy:
- Any exclusionary abnormalities in laboratory values at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat
- Screening standard 12-lead ECG that demonstrates clinically relevant abnormalities; Other Exclusion Criteria:
- Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
Helyszínek itt: Japán
Még 10 másik országban, 135 helyszínen
- Hamamatsu University HospitalHamamatsu, JapánRésztvevőt keres
- Juntendo Tokyo Koto Geriatric Medical CenterKoto-ku, JapánRésztvevőt keres
- Kurume University HospitalKurume, JapánNo longer taking part
- Kyorin University HospitalMitaka, JapánRésztvevőt keres
- Niigata University Medical & Dental HospitalNiigata, JapánNo longer taking part
- Osaka Metropolitan University HospitalOsaka, JapánNo longer taking part
- Tohoku University HospitalSendai, JapánNo longer taking part
- Tokyo Medical University HospitalShinjuku-ku, JapánRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body.
A teljes eredeti leírásKevesebb
Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.
This study is seeking participants who:
* Are 12 years of age or older (Part 1) * Are 12 to less than 18 years (Part 2) * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata
About 550 participants will take part in Part 1 of this study. About 80 participants will take part in Part 2 of this study.
In Part 1, participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily.
The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective.
In Part 2, all eligible participants will receive ritlecitinib 100 mg taken by mouth once daily. The data from this part of the study will be combined with the data from Part 1 of the study to help to see if the 100 mg dose of ritlecitinib is safe and effective in adolescent patients with alopecia areata.
People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as:
* alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes (Part 1 only). Participants will also be asked to complete questionnaires about their alopecia areata.
A vizsgálat 5 csoportja
- Ritlecitinib 50 mgA vizsgált kezelés
Participants in Part 1 will be randomized to Ritlecitinib 50 mg QD for 24 weeks. Depending on response status at Week 24 (ie, whether the participant has a SALT score of less than or equal to 20), the participant may be re-randomized to Ritlecitinib 50 mg QD or Ritlecitinib 100 mg QD for another 24 weeks. Data from participants who are non-responders (ie, had a SALT score greater than 20) at Week 24 and re-randomized to Ritlecitinib 50 mg will be augmented with data from an External Ritlecitinib 50 mg QD Group for comparisons at Week 48. The External Ritlecitinib 50 mg QD Group will be constructed using patient-level data from the appropriately chosen Pfizer clinical study in participants who received Ritlecitinib 50 mg QD and were non-responders at Week 24 and continued receiving ritlecitinib 50 mg QD up to Week 48. In addition to the active Ritlecitinib 50 mg capsule, a placebo capsule matching the Ritlecitinib 100 mg capsule will be given in order to maintain the blind.
Kezelés: Ritlecitinib 50 mg és Placebo - 100 mg
- External PlaceboNincs vizsgálati kezelés, összehasonlításként
This group will be constructed using participant-level data at Week 24 from placebo groups of the appropriately chosen Pfizer clinical studies of Ritlecitinib in participants with alopecia areata. This data will be used for comparison between each Ritlecitinib dose and placebo at Week 24. As this arm will utilize data from other studies, no participants will be randomized to receive only placebo in this study.
- Ritlecitinib 100 mg (open-label)A vizsgált kezelés
Participants in Part 2 will be assigned to receive one open-label Ritlecitinib 100 mg capsule once daily by mouth for 48 weeks.
Kezelés: Ritlecitinib 100 mg
- Ritlecitinib 100 mgA vizsgált kezelés
Participants in Part 1 will be randomized to Ritlecitinib 100 mg QD for 48 weeks. In addition to the active Ritlecitinib 100 mg capsule, a placebo capsule matching the Ritlecitinib 50 mg capsule will be given in order to maintain the blind.
Kezelés: Ritlecitinib 100 mg és Placebo - 50 mg
- Synthetic PlaceboNincs vizsgálati kezelés, összehasonlításként
This group will be constructed using participant-level data up to Week 36 from the placebo groups of the appropriately chosen Pfizer clinical studies of Ritlecitinib in participants with alopecia areata and a longitudinal model and extrapolation. This data will be used for comparison between Ritlecitinib 100 mg and placebo at Week 36. As this arm will utilize data from other studies, no participants will be randomized to receive only placebo in this study.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- A regiszteradat frissítve
- 2026. október 20.